Illumina (NASDAQ:ILMN) Price Target Cut to $136.00 by Analysts at Morgan Stanley

Illumina (NASDAQ:ILMN) had its target price lowered by Morgan Stanley from $150.00 to $136.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the life sciences company’s stock.

ILMN has been the topic of several other reports. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Robert W. Baird raised their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research report on Thursday, October 17th. Finally, Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $130.00 to $100.00 in a research report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Trading Down 4.1 %

Illumina stock opened at $100.68 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market capitalization of $15.97 billion, a price-to-earnings ratio of -13.11 and a beta of 1.10. Illumina has a one year low of $100.08 and a one year high of $156.66. The company’s fifty day moving average price is $135.90 and its two-hundred day moving average price is $135.48.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, analysts forecast that Illumina will post 4.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. LPL Financial LLC increased its holdings in shares of Illumina by 24.6% during the fourth quarter. LPL Financial LLC now owns 82,867 shares of the life sciences company’s stock worth $11,073,000 after buying an additional 16,339 shares in the last quarter. Guardian Partners Inc. acquired a new stake in shares of Illumina during the fourth quarter worth approximately $2,537,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Illumina during the fourth quarter worth approximately $8,051,000. Sei Investments Co. increased its holdings in shares of Illumina by 3.6% during the fourth quarter. Sei Investments Co. now owns 134,913 shares of the life sciences company’s stock worth $18,028,000 after buying an additional 4,738 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Illumina by 11.5% during the fourth quarter. American Century Companies Inc. now owns 226,852 shares of the life sciences company’s stock worth $30,314,000 after buying an additional 23,338 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.